This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Insel, J. Articles by Mirvis, D. M. Search for Related Content PubMed PubMed Citation Articles by Insel, J. Articles by Mirvis, D. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Angina Social Bookmarking                         What's this?

Efficacy of Pentoxifylline in Patients with Stable Angina Pectoris

Medical Service, Memphis Veterans Administration Medical Center, and Department of Medicine, University of Tennessee, Memphis, Tennessee

A. Arthur Halle

Medical Service, Memphis Veterans Administration Medical Center, and Department of Medicine, University of Tennessee, Memphis, Tennessee

David M. Mirvis

Medical Service, Memphis Veterans Administration Medical Center, and Department of Medicine, University of Tennessee, Memphis, Tennessee

Pentoxifylline, a methyl xanthine derivative, improves symptoms of periph eral vascular disease probably by reducing whole blood viscosity. The authors assessed the value of this agent in treating myocardial ischemia in 11 patients with angiographically documented coronary artery disease and stable angina pectoris. Maximal, symptom limited treadmill exercise stress tests were per formed before and after six weeks of therapy with 1200 mg of pentoxifylline per day. Clinical symptoms improved in 9 [82%] of patients; none developed drug side effects. After therapy, mean total exercise time [7.7±1.3 vs 10.1±1.2 min utes], time to onset of angina [5.5 ±0.9 vs 7.9 ±1.0 minutes], heart rate at onset of angina [93.4±6.7 vs 112.0±10.5 beats/min] and rate at onset of ST depres sion [94.0±5.8 vs 115.9±7.4 beats/min] all increased significantly [p < 0.05]. Mean maximum ST segment depression also decreased [1.6±0.3 vs 1.2±0.4 mm], but the difference was not significant. Thus, pentoxifylline increases exer cise performance in patients with angina pectoris and increases exercise capac ity before development of myocardial ischemia. It may, therefore, be a useful agent for treating ischemic heart disease.

Angiology, Vol. 39, No. 6, 514-519 (1988)
DOI: 10.1177/000331978803900604


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. L. Sonkin, L.-E. Chen, A. V. Seaber, and D. L. Hatchell Vasodilator Action of Pentoxifylline on Microcirculation of Rat Cremaster Muscle Angiology, June 1, 1992; 43(6): 462 - 469. [Abstract] [PDF]

				J. C. Barnett and R. C. Touchon Therapy of Ischemic Cardiomyopathy with Pentoxifylline Angiology, December 1, 1990; 41(12): 1048 - 1052. [Abstract] [PDF]

				M. Armstrong JR, D. Needham, D. L. Hatchell, and R. S. Nunn Effect of Pentoxifylline on the Flow of Polymorphonuclear Leukocytes Through a Model Capillary Angiology, April 1, 1990; 41(4): 253 - 262. [Abstract] [PDF]